How should I manage insomnia in my 14‑year‑old who takes hydroxyzine 25 mg at bedtime and Vyvanse (lisdexamfetamine) 20 mg daily, which began after starting Vyvanse?

Managing Stimulant-Induced Insomnia in an Adolescent

First, adjust the timing and dosing of Vyvanse to minimize sleep disruption, as the FDA label explicitly recommends avoiding afternoon doses due to insomnia potential; if this fails, consider adding melatonin or low-dose doxepin rather than continuing hydroxyzine, which lacks evidence for chronic pediatric insomnia. 1

Immediate Vyvanse Optimization

The Vyvanse FDA label specifically states to "avoid afternoon doses because of the potential for insomnia" 1. For your 14-year-old on 20 mg daily:

• Ensure morning-only administration (ideally upon waking) to maximize the 10-13 hour duration before bedtime 1
• Consider dose reduction to 10 mg if sleep problems persist, as the stimulant practice parameter notes that lowering the last dose or moving it earlier can resolve sleep-onset difficulties 2
• Monitor for behavioral rebound versus true insomnia—if irritability occurs late afternoon, this may represent medication wearing off rather than a sleep disorder 2

Why Hydroxyzine Is Problematic

Hydroxyzine (an antihistamine) is not recommended for chronic insomnia treatment in any age group. The American Academy of Sleep Medicine guidelines explicitly state that "over-the-counter antihistamine or antihistamine/analgesic type drugs are not recommended in the treatment of chronic insomnia due to the relative lack of efficacy and safety data" 2. Additionally, antihistamines have "potential for serious side effects arising from their concurrent anticholinergic properties" 2.

Recent 2024 data shows hydroxyzine is increasingly prescribed for pediatric insomnia despite this lack of evidence 3, but this represents a prescribing trend rather than evidence-based practice.

Evidence-Based Alternatives for Adolescent Insomnia

First-Line: Non-Pharmacologic Approach

• Cognitive behavioral therapy for insomnia (CBT-I) is the standard of care and should be initiated when appropriate 2
• Sleep hygiene optimization: regular sleep-wake schedule, quiet environment, avoiding caffeine/stimulants before bed 2
• These behavioral interventions have "long-lasting outcomes" compared to medications 4

Second-Line: Pharmacologic Options (if behavioral interventions insufficient)

Since no medications are FDA-approved for pediatric insomnia 4, 5, all options are off-label:

Melatonin (2-5 mg):

• Most commonly used in pediatric practice despite adult guidelines recommending against it 2, 5
• May be reasonable for adolescents with stimulant-induced sleep-onset delay 5, 6
• Safer side-effect profile than sedative-hypnotics 5

Low-dose doxepin (3-6 mg):

• The AASM suggests doxepin for sleep maintenance insomnia in adults 2
• Has better evidence than trazodone (which received a negative recommendation) 2
• Minimal anticholinergic effects at low doses compared to other tricyclics 2

Alpha-agonists (clonidine, guanfacine):

• Commonly prescribed in children with ADHD and insomnia 3
• May address both ADHD symptoms and sleep onset if Vyvanse dose reduction isn't sufficient 3

Avoid in Adolescents:

• Benzodiazepines and Z-drugs: Risk of dependence, tolerance, and "tachyphylaxis and risk of misuse preclude long-term use" in children 7
• Trazodone: Despite common use, the AASM specifically recommends against it for insomnia 2
• Continued antihistamines: No evidence for efficacy, anticholinergic risks 2

Clinical Algorithm

1. Optimize Vyvanse timing (strict morning dosing) and consider dose reduction to 10 mg 2, 1
2. Discontinue hydroxyzine (lacks evidence, anticholinergic risks) 2
3. Implement sleep hygiene and behavioral interventions 2
4. If pharmacotherapy needed after 2-4 weeks, trial melatonin 2-5 mg at bedtime 5, 6
5. If melatonin insufficient, consider low-dose doxepin 3-6 mg or alpha-agonist 2, 5, 3
6. Reassess every 2-4 weeks for effectiveness and side effects 2

Critical Caveats

• All sleep medications in adolescents are off-label and should be "part of a comprehensive approach to management" including behavioral therapy 4, 5
• Stimulant-induced insomnia often improves with timing adjustments alone—medication changes may be unnecessary 2
• Monitor for psychiatric comorbidities: 75% of youth with insomnia have comorbid anxiety, depression, or ADHD that may require separate treatment 3
• Follow-up is essential: The relapse rate for insomnia is high, requiring reassessment every few weeks initially, then every 6 months 2